Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00702208 · ClinicalTrials.gov registry record · Phase 2
Feasibility of Delphi Screener for Cervical Cytology
A Phase 2 study, sponsored by Columbia University.
- Completed
- Registry status
- Phase 2
- Development phase
- 198
- Enrollment target
NCT00702208 is a Phase 2 study that has completed, run by Columbia University. The registered enrollment target is 198 participants.
The verdict
NCT00702208, a Phase 2 study, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 198 participants
- Enrollment target
Study Summary
The aim of this study is to see whether a new self-sampling device, the Delphi Screener (Delphi Devices, Scherpenzeel, Netherlands), can be used for cervical cancer screening. The results using the new device will be compared to results using the current gold standard. The gold standard is clinician-collected endo-cervical and ecto-cervical specimens (often referred to as a 'Pap smear'). Additionally, women will be asked about the acceptability of using the device and how easy it is to understand the user instructions. The Delphi Screener is a sterile, plastic, syringe-like device containing buffered saline which allows a woman to collect her own vaginal lavage (to 'self-squirt'). The hypothesis is that the device may work well for cervical cytology and will be acceptable to the women in the study.
Interventions
- DEVICE Delphi Screener
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 198 participants |
| Start Date | 2008-09 |
| Est. Completion | 2010-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00702208
The ClinicalTrials.gov registry entry for NCT00702208 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 198 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Delphi Screener is the first listed.
NCT00702208 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00702208 about?
NCT00702208 is a clinical study titled "Feasibility of Delphi Screener for Cervical Cytology". The aim of this study is to see whether a new self-sampling device, the Delphi Screener (Delphi Devices, Scherpenzeel, Netherlands), can be used for cervical cancer screening. The results using the new device will be compared to results using the current gold standard. The gold standard is clinician...
What is the current status of trial NCT00702208?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 198 participants. The study started on 2008-09. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00702208?
The interventions under investigation include: Delphi Screener (DEVICE).
Who is sponsoring clinical trial NCT00702208?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.